BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) headquartered in San Rafael, will host a conference call for the investment community to discuss the 2Q20 earnings result on 4th August 2020 at 4:30 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.biomarin.com
Earnings Expectation
BioMarin Pharmaceutical Inc. is expected to report second quarter earnings results, after market close, on Tuesday 4th August 2020. Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.11 per share. Looking ahead, the full year income are expected at $ 0.27 per share on the revenues of $ 1899.70 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,850.00 million ~ $ 1,950.00 million
Click Here For More Historical Outlooks Of BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The companys commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome.
